Mechanism — how KPV and BPC-157 differ
KPV (Lysine-Proline-Valine) is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH). Its proposed mechanism in research models centres on anti-inflammatory signalling related to the melanocortin axis — specifically downregulation of pro-inflammatory cytokine response and NF-κB-axis modulation.
BPC-157 (Body Protective Compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of human gastric juice protein. Its proposed mechanism in research models is multi-axis — angiogenic-axis modulation, growth-factor-axis interaction, and broader tissue-repair signalling — with a wider pharmacological footprint than KPV.
Receptor profile
KPV's proposed receptor profile is melanocortin-related, with downstream effects on inflammatory signalling pathways. The tripeptide structure gives it a narrower pharmacological footprint than longer anti-inflammatory peptides.
BPC-157 does not act through a single well-characterised receptor. Published research suggests interactions with multiple growth-factor and angiogenic pathways, which is the proposed basis for its broader tissue-repair research profile.
Pharmacokinetics and half-life
KPV is a short tripeptide with a short native half-life. Research cadences are typically daily or sub-daily; oral, topical and subcutaneous research-administration routes have been reported in the literature.
BPC-157 is a 15-residue peptide with notable stability in gastric conditions — oral, subcutaneous and intraperitoneal research-administration routes are documented. Research cadences vary depending on the route.
Research applications
KPV is widely used in research models of inflammatory bowel conditions, skin and mucosal inflammation, and as a comparator anti-inflammatory peptide in melanocortin-axis studies. The tripeptide structure simplifies analytical work compared with longer peptides.
BPC-157 is widely used in research models of tendon, ligament, muscle and gastrointestinal tissue repair, and in angiogenesis research. The broader proposed mechanism gives it a wider research-application footprint than KPV.
Analytical specification on every Regena batch
Both KPV and BPC-157 ship from Regena only after independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.
Batch COAs for both compounds are published on the Regena lab reports page so a research-peptide buyer can audit the analytical detail before purchase. The /trust/how-to-read-a-coa reference walks through every field on a modern Regena COA.
Handling, reconstitution and stability
Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a 28-day in-use stability window under refrigeration for both compounds.
Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both KPV and BPC-157 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.
When researchers choose KPV vs BPC-157
Researchers choose KPV when the protocol targets melanocortin-related anti-inflammatory signalling specifically — typically mucosal-inflammation, skin-inflammation or IBD research models. Researchers choose BPC-157 when the protocol targets broader tissue-repair, angiogenic-axis or musculoskeletal-repair research applications, or when a multi-axis pharmacological profile is part of the experimental design.
For multi-compound comparator studies, the Regena consultations team will reserve matched-batch inventory of both KPV and BPC-157 against a project timeline so the experimental panel is sourced under a single analytical specification window.
Regulatory and research-use framing
Both KPV and BPC-157 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.
Comparison pages on the Regena site exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.
Frequently asked questions
What is the main difference between KPV and BPC-157?+
KPV (Lysine-Proline-Valine) is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH).
Which has the longer half-life, KPV or BPC-157?+
KPV is a short tripeptide with a short native half-life. Research cadences are typically daily or sub-daily; oral, topical and subcutaneous research-administration routes have been reported in the literature.
Are KPV and BPC-157 the same compound class?+
Both sit in the anti-inflammatory and regenerative peptides category but with distinct receptor profiles and pharmacokinetics — see the receptor-profile section above for the side-by-side detail.
What HPLC purity does Regena release each compound against?+
≥99.0% HPLC main-peak purity for both KPV and BPC-157, with matching mass-spectrometry molecular weight and water content within the published specification for each compound.
Who independently verifies the batches?+
Janoshik Analytical is the default independent verifier for both compounds; orthogonal independent laboratories are used when batch chemistry calls for second-method confirmation.
Can I order matched batches for a comparator study?+
Yes — the Regena consultations team will reserve matched-batch inventory of both compounds against a project timeline so the experimental panel is sourced under a single analytical specification window.
Are these peptides approved for human use?+
No. Both are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption, and are not dispensed against a prescription.
Where can I see the current batch COAs for both compounds?+
On the /coa lab reports page, indexed by compound and batch number. New batches appear within 24 hours of independent release.
Recommended next — keep comparing
Hand-picked links our research customers most often open after this page.